© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
May 20, 2022
An end-of-week review of retina news and stories from May 13 to May 20.
May 11, 2022
Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.
May 03, 2022
Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
April 30, 2022
A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.
April 13, 2022
The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.
April 12, 2022
According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.
April 03, 2022
The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.
March 30, 2022
Lower dose performs as effectively as a higher dose when treating ROP.
March 28, 2022
In the face of the COVID-19 pandemic, the procedure required adjustments.
March 23, 2022
Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.